Issues and updates: Evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer

Modern Pathology

Volumn 23, Issue SUPPL. 2, 2010, Pages

  Allred, D Craig ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen receptor; HER2; Immunohistochemistry; Progesterone receptor

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MICROARRAY ANALYSIS; ONCOGENE; PARTIAL MASTECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 77951991757     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.55     Document Type: Review

References (80)

1. Rampaul RS, Pinder SE, Elston CW, et al. Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team. Eur J Surg Oncol 2001;27:229-238.
2. Mirza AN, Mirza NQ, Vlastos G, et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002;235:10-26.
3. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohisto-chemical analysis. Modern Pathol 1998;11:155-168.
4. Chang JC, Hilsenbeck SG. Prognostic and predictive markers. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast, Vol., 3rd edn. Lippincott Williams and Wilkins: Philadelphia, 2004, pp 675-696.
5. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Patholo-gists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-978.
6. Bast RC, Ravdin P, Hayes DF, et al. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines for the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-1878.
7. Carlson RW, Edge SB, Theriault FL, et al. NCCN Breast Cancer Practice Guidelines Panel. Cancer Control 2001; 8 (6 Suppl 2) : 54-61.
8. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
9. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu onco-gene. Science 1985;230:1132-1139.
10. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185, 000-Mr tumour antigen. Nature 1984;312:513-516.
11. Gullick WJ, Srinivasan R. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat 1998;52:43-53.
12. Menard S, Tagliabue E, Campiglio M, et al. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000;82:150-162.
13. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000;19:6102-6114.
14. Allred DC, Swanson PE. Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 2000;113:171-175.
15. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-2356.
16. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 2008;44:2806-2812.
17. Conlin AK, Seidman AD. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. Clin Breast Cancer 2008;8:215-223.
18. Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 2008;5:531-542.
19. Yamashiro H, Toi M. Update of evidence in chemotherapy for breast cancer. Int J Clin Oncol 2008;13:3-7.
20. Frankel C. Choosing the appropriate breast cancer therapy for today's breast cancer patient. Semin Oncol Nurs 2007; 23 (4 Suppl 2) : S3-S9.
21. Dhesy-Thind B, Pritchard KI, Messersmith H, et al. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat 2008;109:209-229. (Pubitemid 351644854)
22. Engel RH, Kaklamani VG. HER2-positive breast cancer: current and future treatment strategies. Drugs 2007;67:1329-1341.
23. Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology 2009;23:133-142.
24. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-398.
25. Mackey J, McLeod D, Ragaz J, et al. Adjuvant targeted therapy in early breast cancer. Cancer 2009;115:1154-1168.
26. Mariani G, Fasolo A, De Benedictis E, et al. Trastuzu-mab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 2009;6:93-104.
27. Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 2008;8:324-333.
28. Dahabreh IJ, Linardou H, Siannis F, et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 2008;13:620-630.
29. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004;291:1972-1977. (Pubitemid 38544278)
30. Press M, Spaulding B, Groshen S, et al. Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids 2002;67:799-813.
31. Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia 2009;14:55-66.
32. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzu-mab. Breast Cancer Res Treat 2005;93:3-11.
33. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:3032-3038.
34. Middleton LP, Price KM, Puig P, et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immuno-histochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med 2009;133:775-780.
35. Clarke RB. Steroid receptors and proliferation in the human breast. Steroids 2003;68:789-794.
36. Fuqua SAW, Schiff S. The biology of estrogen receptors. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast Vol., 3rd edn. Lippincott Williams and Wilkins: Philadelphia, 2004, pp 585-602.
37. Keen JC, Davidson NE. The biology of breast carcinoma. Cancer 2003; 97 (3 Suppl) : 825-833.
38. Elledge RM, Allred DC. Clinical aspects of estrogen and progesterone receptors. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast, Vol., 3rd edn. Lippincott Williams and Wilkins: Philadelphia, 2004, pp 602-617.
39. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
40. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
41. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: a hypothesis-generating study. J Clin Oncol 2005;23:7512-7517.
42. Buzdar A, Vergote I, Sainsbury R. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmeno-pausal women. Breast J 2004;10:211-217.
43. Rhodes A, Jasani B, Balaton AJ, et al. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 2000;53:688-696.
44. Rhodes A, Jasani B, Balaton AJ, et al. Immunohisto-chemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 2000;53:292-301.
45. Rhodes AR, Jasani B, Balaton AJ, et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Am J Clin Pathol 2001;115:44-58.
46. Allred DC. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. Oncologist 2008;13:1134-1136.
47. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008; 21 (Suppl 2) : S8-S15.
48. Hede K. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst 2008;100:836-837, 844.
49. Mathews AW. Bad cancer tests drawing scrutiny. Wall St J 2008, (Friday, 4 January; Sect. B1-B2).
50. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991;83:1-9.
51. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-1466.
52. Cheang MC, Treaba DO, Speers CH, et al. Immuno-histochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 2006;24:5637-5644.
53. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
54. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004;17:1545-1554.
55. Phillips T, Murray G, Wakamiya K, et al. Development of standard estrogen and progesterone receptor im-munohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol 2007;15:325-331.
56. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007;25:3846-3852.
57. Viale G, Regan MM, Maiorano E, et al. Chemoendo-crine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 2008;26:1404-1410.
58. Hammond EMH, Allred DC, Dowsett M, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immuno-histochemical testing of estrogen/progesterone receptors in breast cancer. J Clin Oncol and Arch Pathol Lab Med (in press).
59. Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 2004;6:240-245.
60. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR) by ligand-binding assay compared with ER, PgR, and pS2 by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000;89:111-117.
61. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochem-ical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol 2005;123:16-20.
62. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5, 993 breast cancers. Am J Clin Pathol 2005;123:21-27.
63. Allred DC, Mohsin SK. ER expression is not bimodal in breast cancer. Am J Clin Pathol 2005;124:474-475; author reply 5-6.
64. Albain K, Barlow W, O'Malley F, et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorour-acil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PR-receptor-positive breast cancer: mature outcomes and new biological correlates on phase III Intergroup Trial 0100 (SWOG-8814). Breast Cancer Res Treat 2004; 88 (Suppl 1) : A37.
65. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:1059-1065.
66. Allred DC, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24. Breast Cancer Res Treat 2002; 76 (S1) : S36 (no. 0).
67. Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with hormone receptor-positive DCIS: a study based on NSABP protocol B-24 (Submitted February 2010).
68. Badve S, Baehner FL, Gray R, et al. Estrogen and progesterone receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse polymerase chain reaction by central laboratory. J Clin Oncol 2008;26:2473-2481.
69. Oh DS, Troester MA, Usary J, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006;24:1656-1664.
70. Anderson E. Progesterone receptors-animal models and cell signaling in breast cancer: the role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 2002;4:197-201.
71. Jacobsen BM, Richer JK, Sartorius CA, et al. Expression profiling of human breast cancers and gene regulation by progesterone receptors. J Mammary Gland Biol Neoplasia 2003;8:257-268.
72. Love RR, Ba NB, Allred DC, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 2002;20:2559-2566.
73. Bardou V-J, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-1979.
74. Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005;23:7721-7735.
75. Schiff R, Massarweh SA, Shou J, et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004; 10 (1 Pt 2) : 331S-336S.
76. Kampa M, Pelekanou V, Castanas E. Membrane-initiated steroid action in breast and prostate cancer. Steroids 2008;73:953-960.
77. Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 2008;108:351-361.
78. Silva CM, Shupnik MA. Integration of steroid and growth factor pathways in breast cancer: focus on signal transducers and activators of transcription and their potential role in resistance. Mol Endocrinol 2007;21:1499-1512.
79. Song RX. Membrane-initiated steroid signaling action of estrogen and breast cancer. Semin Reprod Med 2007;25:187-197.
80. Song RX, Santen RJ. Membrane initiated estrogen signaling in breast cancer. Biol Reprod 2006;75:9-16.